KBP-042
N/A
Report date: 2023/07/31 20:00:35
NME
Base Information
Drug NameKBP-042
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory +[6]
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUnigene Laboratories Inc
China Registration ClassN/A
Develop Information
Active CompaniesN/A
Inactive CompaniesNordic Bioscience A/SEli Lilly And CompanyKeybioscience Ag
Active IndicationsN/A
Inactive Indications
Other Information
ATC CodeN/A
Related LinksN/A